Abstract: Disclosed herein are methods for preparing clinically useable target cells for use in achieving a clinical effect in patients. The protocols disclosed herein have been shown to improve cell yield during collection of target cells, transport of target cells, storage of target cells, and use of target cells. Also disclosed herein are kits and methods for testing patients and preparing clinically useable target cells for use in achieving a clinical effect in patients. The kits and protocols therein improve cell yield during collection of target cells, transport of target cells, storage of target cells, and use of target cells.

Abstract: A method comprising administering to a subject a composition comprising an isolated microRNA having a sequence selected from the group consisting of miR-19a-3p (SEQ ID NO:1); miR-103a-3p (SEQ ID NO:2); miR-106b-5p (SEQ ID NO:3); miR-146a-5p (SEQ ID NO:4); miR-223-5p (SEQ ID NO:5); miR-4497 (SEQ ID NO:6); miR-1303 (SEQ ID NO:7); miR-619-5p (SEQ ID NO:8); miR-1273f (SEQ ID NO:9); miR-7851-3p (SEQ ID NO:10); a functional variant thereof; and combinations thereof.

Abstract: A pharmaceutical formulation comprising exosomes derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising a microvesicles derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising an exosome-derived and/or microvesicle derived molecule and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles.

Abstract: Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg2+/Mn2+ dependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.

Abstract: Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg2+/Mn2+ dependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.

Abstract: A method comprising administering to a subject a composition comprising an isolated microRNA having a sequence selected from the group consisting of miR-19a-3p (SEQ ID NO:1); miR-103a-3p (SEQ ID NO:2); miR-106b-5p (SEQ ID NO:3); miR-146a-5p (SEQ ID NO:4); miR-223-5p (SEQ ID NO:5); miR-4497 (SEQ ID NO:6); miR-1303 (SEQ ID NO:7); miR-619-5p (SEQ ID NO:8); miR-1273f (SEQ ID NO:9); miR-7851-3p (SEQ ID NO:10); a functional variant thereof; and combinations thereof.